In Japan, where over 70% of individuals with diabetes are aged 65 or older and often exhibit a non-obese phenotype with impaired insulin secretion, dipeptidyl peptidase-4 inhibitors remain a cornerstone therapy due to their ability to enhance insulin secretion without increasing hypoglycemia risk. The gene discussed is INS; the disease is Hypoglycemia.